NUP160 - SLC43A3 Is a Novel Recurrent Fusion Oncogene in Angiosarcoma

2015-11-01 20:45:44

Cancer Research; 1 November 2015: DOI:10.1158/0008-5472.CAN-15-0418

Naoki Shimozono, Masatoshi Jinnin, Mamiko Masuzawa, Mikio Masuzawa, Zhongzhi Wang, Ayaka Hirano, Yukiko Tomizawa, Tomomi Etoh-Kira, Ikko Kajihara, Miho Harada, Satoshi Fukushima, and Hironobu Ihn


Angiosarcoma is a malignant vascular tumor originating from endothelial cells of blood vessels or lymphatic vessels. The specific driver mutations in angiosarcoma remain unknown. In this study, we investigated this issue by transcriptome sequencing of patient-derived angiosarcoma cells (ISO - HAS), identifying a novel fusion gene NUP160 - SLC43A3 found to be expressed in 9 of 25 human angiosarcoma specimens that were examined. In tumors harboring the fusion gene, the duration between the onset of symptoms and the first hospital visit was significantly shorter, suggesting more rapid tumor progression. Stable expression of the fusion gene in nontransformed human dermal microvascular endothelial cells elicited a gene-expression pattern mimicking ISO-HAS cells and increased cell proliferation, an effect traced in part to NUP160 truncation. Conversely, RNAi-mediated attenuation of NUP160 in ISO-HAS cells decreased cell number. Confirming the oncogenic effects of the fusion protein, subcutaneous implantation of NUP160 - SLC43A3-expressing fibroblasts induced tumors resembling human angiosarcoma. Collectively, our findings advance knowledge concerning the genetic causes of angiosarcoma, with potential implications for new diagnostic and therapeutic approaches.

To Access Article, Click Here